scholarly journals Characterization of the Human Artemis Promoter by Heterologous Gene Expression In Vitro and In Vivo

2011 ◽  
Vol 30 (10) ◽  
pp. 751-761 ◽  
Author(s):  
Megan M. Multhaup ◽  
Sweta Gurram ◽  
Kelly M. Podetz-Pedersen ◽  
Andrea D. Karlen ◽  
Debra L. Swanson ◽  
...  
Keyword(s):  
Gene Expression ◽  
Heterologous Gene Expression ◽  
Heterologous Gene

scholarly journals Optimization of Heterologous Gene Expression for In Vitro Evolution

BioTechniques ◽  
2001 ◽  
Vol 30 (3) ◽  
pp. 474-476 ◽  
Author(s):  
Ichiro Matsumura ◽  
Mark J. Olsen ◽  
Andrew D. Ellington
Keyword(s):  
Gene Expression ◽  
Heterologous Gene Expression ◽  
Heterologous Gene ◽  
In Vitro Evolution

Heterologous gene expression and characterization of two serine hydroxymethyltransferases from Thermoplasma acidophilum

Extremophiles ◽  
2021 ◽  
Author(s):  
Ilma Fauziah Ma’ruf ◽  
Yuka Sasaki ◽  
Anastasia Kerbs ◽  
Jochen Nießer ◽  
Yu Sato ◽  
...  
Keyword(s):  
Gene Expression ◽  
Heterologous Gene Expression ◽  
Heterologous Gene ◽  
Thermoplasma Acidophilum

scholarly journals Quantifying cellular capacity to identify gene expression designs with reduced burden

2014 ◽  
Author(s):  
Francesca Ceroni ◽  
Rhys J R Algar ◽  
Guy-Bart Stan ◽  
Tom Ellis
Keyword(s):  
Gene Expression ◽  
Real Time ◽  
Heterologous Gene Expression ◽  
Heterologous Gene ◽  
E Coli ◽  
Equivalent Expression ◽  
Significant Burden ◽  
Cellular Capacity ◽  
Identify Gene Expression

Heterologous gene expression can be a significant burden to cells, consuming resources and causing decreased growth and stability. We describe here anin vivomonitor that tracksE. colicapacity changes in real-time and can be used to assay the burden synthetic constructs and their parts impose. By measuring capacity, construct designs with reduced burden can be identified and shown to predictably outperform less efficient designs, despite having equivalent expression outputs.

scholarly journals The GARDpotency Assay for Potency-Associated Subclassification of Chemical Skin Sensitizers—Rationale, Method Development, and Ring Trial Results of Predictive Performance and Reproducibility

2020 ◽  
Vol 176 (2) ◽  
pp. 423-432
Author(s):  
Robin Gradin ◽  
Angelica Johansson ◽  
Andy Forreryd ◽  
Emil Aaltonen ◽  
Anders Jerre ◽  
...  
Keyword(s):  
Gene Expression ◽  
Method Development ◽  
Expression Profiles ◽  
Hazard Identification ◽  
Predictive Toxicology ◽  
Ring Trial ◽  
Biomarker Signature

Abstract Proactive identification and characterization of hazards attributable to chemicals are central aspects of risk assessments. Current legislations and trends in predictive toxicology advocate a transition from in vivo methods to nonanimal alternatives. For skin sensitization assessment, several OECD validated alternatives exist for hazard identification, but nonanimal methods capable of accurately characterizing the risks associated with sensitizing potency are still lacking. The GARD (Genomic Allergen Rapid Detection) platform utilizes exposure-induced gene expression profiles of a dendritic-like cell line in combination with machine learning to provide hazard classifications for different immunotoxicity endpoints. Recently, a novel genomic biomarker signature displaying promising potency-associated discrimination between weak and strong skin sensitizers was proposed. Here, we present the adaptation of the defined biomarker signature on a gene expression analysis platform suited for routine acquisition, confirm the validity of the proposed biomarkers, and define the GARDpotency assay for prediction of skin sensitizer potency. The performance of GARDpotency was validated in a blinded ring trial, in accordance with OECD guidance documents. The cumulative accuracy was estimated to 88.0% across 3 laboratories and 9 independent experiments. The within-laboratory reproducibility measures ranged between 62.5% and 88.9%, and the between-laboratory reproducibility was estimated to 61.1%. Currently, no direct or systematic cause for the observed inconsistencies between the laboratories has been identified. Further investigations into the sources of introduced variability will potentially allow for increased reproducibility. In conclusion, the in vitro GARDpotency assay constitutes a step forward for development of nonanimal alternatives for hazard characterization of skin sensitizers.

Characterization of chromosomal integration sites for heterologous gene expression inSaccharomyces cerevisiae

Yeast ◽  
2009 ◽  
Vol 26 (10) ◽  
pp. 545-551 ◽  
Author(s):  
Dongmei Bai Flagfeldt ◽  
Verena Siewers ◽  
Le Huang ◽  
Jens Nielsen
Keyword(s):  
Gene Expression ◽  
Heterologous Gene Expression ◽  
Heterologous Gene ◽  
Chromosomal Integration ◽  
Integration Sites
Sign in / Sign up

Export Citation Format

Share Document